ATRC (AtriCure) Beneish M-Score: -2.91 (As of Jun. 24, 2026)


ATRC AtriCure Inc ATRC
76 GF Score
Price $28.26
GF Value $39.73
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is AtriCure Beneish M-Score?

AtriCure ATRC -0.63% 76 Beneish M-Score is -2.91 as of Jun. 24, 2026. GuruFocus rates ATRC with a GF Score™ of 76/100 and a GF Value™ of $39.73 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 765 Medical Devices & Instruments companies, AtriCure ranks better than 73.99% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.91 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for AtriCure's Beneish M-Score or its related term are showing as below:

ATRC' s Beneish M-Score Range Over the Past 10 Years
Min: -2.94   Med: -2.66   Max: -2.22
Current: -2.91

During the past 13 years, the highest Beneish M-Score of AtriCure was -2.22. The lowest was -2.94. And the median was -2.66.


AtriCure Beneish M-Score Historical Data

* Premium members only.

The historical data trend for AtriCure's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AtriCure Beneish M-Score Chart

AtriCure Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.51 -2.45 -2.63 -2.79 -2.91

AtriCure Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.84 -2.91 -2.90 -2.91 -2.91

ATRC vs STAA, NNNN, KMTS: Beneish M-Score Comparison

For the Medical Instruments & Supplies subindustry, AtriCure's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AtriCure Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AtriCure's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where AtriCure's Beneish M-Score falls into.


ATRC
76GF Score
AtriCure Inc ATRC
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AtriCure Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of AtriCure for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9792+0.528 * 0.9888+0.404 * 0.8941+0.892 * 1.1501+0.115 * 0.9254
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9415+4.679 * -0.108361-0.327 * 0.9808
=-2.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was $71.3 Mil.
Revenue was 141.249 + 140.5 + 134.269 + 136.139 = $552.2 Mil.
Gross Profit was 109.311 + 105.337 + 101.332 + 101.482 = $417.5 Mil.
Total Current Assets was $313.7 Mil.
Total Assets was $644.0 Mil.
Property, Plant and Equipment(Net PPE) was $46.2 Mil.
Depreciation, Depletion and Amortization(DDA) was $20.7 Mil.
Selling, General, & Admin. Expense(SGA) was $319.5 Mil.
Total Current Liabilities was $73.2 Mil.
Long-Term Debt & Capital Lease Obligation was $71.8 Mil.
Net Income was 0.108 + 1.756 + -0.267 + -6.19 = $-4.6 Mil.
Non Operating Income was -0.037 + 0.042 + 0.009 + 0.812 = $0.8 Mil.
Cash Flow from Operations was -3.996 + 20.027 + 26.716 + 21.617 = $64.4 Mil.
Total Receivables was $63.3 Mil.
Revenue was 123.62 + 124.277 + 115.91 + 116.269 = $480.1 Mil.
Gross Profit was 92.628 + 92.619 + 86.793 + 86.844 = $358.9 Mil.
Total Current Assets was $251.5 Mil.
Total Assets was $591.6 Mil.
Property, Plant and Equipment(Net PPE) was $48.2 Mil.
Depreciation, Depletion and Amortization(DDA) was $19.4 Mil.
Selling, General, & Admin. Expense(SGA) was $295.1 Mil.
Total Current Liabilities was $61.2 Mil.
Long-Term Debt & Capital Lease Obligation was $74.6 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(71.312 / 552.157) / (63.323 / 480.076)
=0.129152 / 0.131902
=0.9792

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(358.884 / 480.076) / (417.462 / 552.157)
=0.747557 / 0.756057
=0.9888

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (313.693 + 46.185) / 643.988) / (1 - (251.484 + 48.207) / 591.631)
=0.441173 / 0.493449
=0.8941

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=552.157 / 480.076
=1.1501

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(19.365 / (19.365 + 48.207)) / (20.72 / (20.72 + 46.185))
=0.286583 / 0.309693
=0.9254

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(319.513 / 552.157) / (295.073 / 480.076)
=0.578663 / 0.614638
=0.9415

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((71.784 + 73.191) / 643.988) / ((74.573 + 61.221) / 591.631)
=0.225121 / 0.229525
=0.9808

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-4.593 - 0.826 - 64.364) / 643.988
=-0.108361

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

AtriCure has a M-score of -2.91 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.91 mean?
AtriCure (ATRC) has a Beneish M-Score of -2.91 as of Jun. 24, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on AtriCure and its competitors. According to the industry distribution chart, AtriCure ranks #199 out of 765 companies in the Medical Devices & Instruments industry, placing it in the top 26%.
Is AtriCure's Beneish M-Score too high?
AtriCure's current Beneish M-Score is -2.91. Based on the distribution chart, AtriCure ranks #199 out of 765 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, AtriCure has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AtriCure's Beneish M-Score compare to STAA and NNNN?
According to the Medical Devices & Instruments industry distribution chart, AtriCure ranks #199 out of 765 companies for Beneish M-Score. This puts AtriCure in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on AtriCure and its competitors. AtriCure's current Beneish M-Score is -2.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AtriCure stock overvalued right now?
Based on GuruFocus' analysis, AtriCure (ATRC) is currently considered Modestly Undervalued. The stock's GF Value™ is $39.73, compared to a current price of $28.26 — trading 28.9% below its estimated fair value. The current Beneish M-Score is -2.91. AtriCure's overall GF Score™ is 76/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For AtriCure (ATRC), the current Beneish M-Score is -2.91 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AtriCure (ATRC) Overvalued in 2026?

Based on GuruFocus' analysis, AtriCure stock appears to be undervalued. The current stock price of $28.26 is trading 28.9% below its estimated GF Value™ of $39.73. GuruFocus considers AtriCure to be Modestly Undervalued.

Key valuation signals for ATRC:

  • Beneish M-Score: -2.91
  • GF Value™: $39.73 vs. price of $28.26 (28.9% below fair value)
  • GF Score™: 76/100 with 1 warning sign

No single metric tells the full story. See the ATRC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AtriCure Business Description

Address 7555 Innovation Way, Mason, OH, USA, 45040
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
76GF Score

Get the complete analysis for ATRC

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.26
Price
$39.73
GF Value